Beijing's life science park home to medical and health giants

The story of BeiGene, one of China's leading biotech enterprises and co-founded by National Institute of Biological Sciences, Beijing and a clinical CRO (contract research organization) enterprise, is a story between scientists and entrepreneurs. Founded in 2010, BeiGene has been listed in NASDAQ, Hong Kong and Shanghai, the first Chinese enterprise to reach this mark. A new research and development center covering 20,000 square meters has been approved and the construction will start in September.

InnoCare Pharma was listed in 2020, only five years after operating in the park. Its first breakthrough drug got approved by the nation before listing.

According to Jin, there are more than 50 ventures co-founded by scientists and entrepreneurs like BeiGene in the park. "Scientific research can be transformed into products only by linking them to capital, intermediary services and CRO services," said Jin.

There are more than 500 medical and health enterprises in the park and more than 800 in Changping district. The district is aiming to earn more than 140 billion yuan from the medical and health industry and an area of more than 10,000 mu to locate the industry by the end of the 14^thFive-Year Plan (2021-25).